CELCUITY ANNOUNCES FDA APPROVAL OF REVTORPYK™ (GEDATOLISIB) FOR THE TREATMENT OF HR+/HER2-, PIK3CA WILD-TYPE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Reuters · 2d ago

Please log in to view news